Merck bets on Google AI
- Merck announced a partnership with Google Cloud to accelerate enterprise AI across R&D and operations. - The company said it may invest as much as $1 billion over several years in AI infrastructure and licensing. - The move signals big pharma doubling down on AI platforms and could raise digital‑data expectations for suppliers and partners ( ).
Merck is handing Google Cloud a central role in its next wave of artificial intelligence spending, in a deal that could reach $1 billion. (merck.com) The companies announced the partnership on April 22 at Google Cloud Next in Las Vegas. Merck said the multi-year investment will fund AI infrastructure, software licensing and Google engineers working with Merck teams. (googlecloudpresscorner.com) Merck said it will deploy Google Cloud’s Gemini Enterprise tools across research and development, manufacturing, commercial operations and corporate functions. Reuters reported the spending could total as much as $1 billion over several years. (reuters.com) In plain terms, Merck is buying more than a chatbot. The company is building what it calls an “agentic” system, meaning software that can draft, search, summarize and route work across internal systems with less human prompting. (merck.com) Drugmakers have been using machine learning for years in chemistry, clinical-trial planning and factory operations. What changed in 2024 and 2025 was the rise of large language models that can work across documents, databases and workflows used by scientists, lawyers and supply-chain teams. (googlecloudpresscorner.com) Merck tied the Google deal to a broad internal overhaul rather than a single lab project. The company said the goal is to strengthen its “digital backbone” for 75,000 employees worldwide. (prnewswire.com) The timing lines up with a wider race in big pharma to use AI beyond early drug discovery. Fierce Pharma reported Merck’s rollout will touch manufacturing, commercial teams and corporate functions as the company prepares for a heavy period of new product launches. (fiercepharma.com) The deal also puts pressure on the less visible parts of the drug business. If Merck standardizes more data and workflows on Google systems, contract manufacturers, research partners and suppliers may face tighter demands on how they format, share and govern data. (reuters.com) Google, for its part, gets a marquee pharmaceutical customer at a time when cloud providers are competing to turn generative AI pilots into long-term enterprise contracts. Merck is betting that the payoff will show up not just in research, but in how the whole company runs. (googlecloudpresscorner.com)
